JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/16.05.25 Stock JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/16.05.25
Add to a list
To use this feature you must be a member
Log inSign up

JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/16.05.25 Stock

Warrant

DE000JB8U1B7

Market Closed - Börse Stuttgart 02:55:18 2024-06-27 EDT
0.16 EUR 0.00% Intraday chart for JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/16.05.25
Current month+14.29%
1 month-5.88%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/16.05.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
More news

Quotes 5-day view

Date Price Change
24-06-27 0.16 0.00%
24-06-26 0.16 0.00%
24-06-25 0.16 -5.88%
24-06-24 0.17 +21.43%
24-06-21 0.14 +7.69%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 02:55 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
Issuer J.P. Morgan
WKN JB8U1B
ISINDE000JB8U1B7
Date issued 2023-11-30
Strike 50 $
Maturity 2025-05-16 (323 Days)
Parity 10 : 1
Emission price 0.53 €
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.78 €
Lowest since issue 0.13 €
Spread 0.01 €
Spread %6.67%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.51 USD
Average target price
53.19 USD
Spread / Average Target
+28.15%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant